Trastuzumab and Lung Cancer

A naked antibody alone just doesn't cut it in terms of response rate and survival. In lung cancer, we've seen some response in the 10 to 20 percent range with Trastuzumab-Tutuzumab. The weak effect of those antibodies on inhibition is then eliciting an immune response that may still be targeting.